Amarin | AMRN - Net Income

Stock Price
14.56
Daily Change
-0.22 -1.49%
Monthly
-1.09%
Yearly
37.62%
Q2 Forecast
14.12

Amarin reported $-1.22M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amarin USD -1.22M 6.51M Dec/2025
AstraZeneca USD 3.08B 754M Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -93M 136M Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Neurocrine Biosciences USD 197.9M 44.2M Mar/2026
Novartis USD 3.16B 747M Mar/2026